Impact News +++ Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and... (GlobeNewswire EN) +++ REZOLUTE Aktie +4,02%

REZOLUTE Aktie

>REZOLUTE Aktienkurs

3.86 EUR (TradegateBSX)

Ask: 3.94 EUR / 1100 Stück

Bid: 3.78 EUR / 1100 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REZOLUTE Aktie über LYNX handeln

Intraday

1 Jahr

>REZOLUTE Performance

1 Woche: +10,8%

1 Monat: -19,9%

3 Monate: -14,2%

6 Monate: +24,1%

1 Jahr: -60,5%

laufendes Jahr: +65,1%

>REZOLUTE Aktie

Profil:

Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclon..
>Volltext..

Insiderhandel:

>REZOLUTE Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>REZOLUTE Peer Group

Gesundheit, Antikörper- Behandlung, Endokrine Erkrankungen (Hormonstörungen), Stoffwechselerkrankungen (Diabetes/ Adipositas)

>REZOLUTE Chart & Kurs - NASDAQ

>REZOLUTE News

13.11.26 - 12:30	Rezolute prices $100M public offering of common stock and pre-funded warrants (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.26 - 12:21	Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire EN)
	Transaction led by Frazier Life Sciences with participation from new and existing funds...

13.11.26 - 12:21	Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism (GlobeNewswire EN)
	Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation...

09.11.26 - 15:42	Rezolute auf Guggenheim-Konferenz: FDA-Fortschritte stärken Aussichten bei seltenen Erkrankungen (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.26 - 06:30	Rezolute GAAP EPS of -$0.18 in-line (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.11.26 - 13:33	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:...

14.10.26 - 22:06	Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire EN)
	Topline results expected mid-December 2026...

06.10.26 - 21:30	Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.10.26 - 13:01	Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism (GlobeNewswire EN)
	The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities ...

24.09.26 - 22:12	Rezolute GAAP EPS of -$0.20 misses by $0.05 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.09.26 - 22:06	Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
	REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026....

09.09.26 - 20:33	Rezolute says late-stage trial data for lead asset remains under FDA review (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.07.26 - 13:33

Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire EN)

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026....

04.06.26 - 19:45	RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? (Zacks)
	Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support....

04.06.26 - 13:33

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society (GlobeNewswire EN)

REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced four presentations at the upcoming Annual Meeting of the Endocrine Society (ENDO) being held June 13-16, 2026, in Chicago, IL....

03.06.26 - 17:36	Rezolute upgraded at Citizens after late-stage trial data for lead asset (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.06.26 - 18:30	Rezolute rises after late-stage trial update (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.26 - 22:48	Rezolute GAAP EPS of -$0.16 beats by $0.02 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.05.26 - 13:03	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:...

01.05.26 - 18:18	Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting (GlobeNewswire EN)
	Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints ...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Um in der Gesellschaft etwas zu gelten, setzt man alles daran, so zu tun, als gelte man dort schon etwas. - François VI. Duc de La Rochefoucauld

Partner: >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram